[
    {
        "file_name": "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_DevelopmentAgreement.txt",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.39 \"Commercially Reasonable Efforts\" means with respect to [***].",
                "changed_text": "1.39 \"Commercially Reasonable Efforts\" means with respect to [***]. Notwithstanding the foregoing, for Harpoon, Commercially Reasonable Efforts shall mean any effort it deems fit, regardless of cost or potential outcome.",
                "explanation": "This change introduces ambiguity by defining Commercially Reasonable Efforts in two conflicting ways, one vague and standard, the other giving Harpoon unilateral discretion. This could lead to disputes about Harpoon's obligations.",
                "location": "ARTICLE 1 DEFINITIONS"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "6.14 [***] The development and regulatory milestone payments, first commercial sales milestone payments, sales-based milestone payments and royalties in Sections 6.2, 6.3 6.4, and 6.5 shall not apply at the same rates to Development and Commercialization of Licensed Compounds or Licensed Products [***] for eligibility to be treated for such disease, state, or condition with a Licensed Compound or Licensed Product or for monitoring patients who are or have been treated with a Licensed Compound or Licensed Product. In the event that a Licensed Compound or Licensed Product is Developed for any such purposes, [***] for the sale of such Licensed Product that [***] of such Licensed Product and [***], as applicable; provided that, for clarity, any such [***] [***] under this Agreement with respect to Licensed Compounds or Licensed Products that are [***].",
                "changed_text": "6.14 [***] The development and regulatory milestone payments, first commercial sales milestone payments, sales-based milestone payments and royalties in Sections 6.2, 6.3 6.4, and 6.5 shall not apply at the same rates to Development and Commercialization of Licensed Compounds or Licensed Products [***] for eligibility to be treated for such disease, state, or condition with a Licensed Compound or Licensed Product or for monitoring patients who are or have been treated with a Licensed Compound or Licensed Product. In the event that a Licensed Compound or Licensed Product is Developed for any such purposes, [***] for the sale of such Licensed Product that [***] of such Licensed Product and [***], as applicable; provided that, for clarity, any such [***] [***] under this Agreement with respect to Licensed Compounds or Licensed Products that are [***]. However, for avoidance of doubt, milestone and royalty payments may be adjusted to the discretion of the parties involved in this contract.",
                "explanation": "The change introduces a contradiction by adding that milestone payments and royalties may be adjusted to the discretion of the parties. It directly conflicts with the initial statement specifying which payments should not be subject to the previously mentioned adjustment. This creates internal uncertainty.",
                "location": "ARTICLE 6 PAYMENTS AND RECORDS"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "3.4 Post-Exercise Development Activities. Following the License Option Exercise Closing Date, except for Harpoon's responsibilities in completing the Initial Development Activities and delivering the Final Development Report, AbbVie shall have the sole right to Develop and Manufacture (and shall control all aspects of Development and Manufacturing), including seeking Regulatory Approvals for, Licensed Compounds and Licensed Products in the Field and in the Territory and, for clarity, Harpoon and its Affiliates shall have no right to do so. Following the License Option Exercise Closing Date, AbbVie shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for [***] Licensed Product for [***] for use in [***] Major Market. AbbVie shall have the right to satisfy its diligence obligations under this Section 3.4 through its Affiliates or Sublicensees. Except as set forth in this Section 3.4, AbbVie shall have no other diligence obligations, express or implied, with respect to the Development of the Licensed Compounds or Licensed Products in the Territory. Following the License Option Exercise Closing Date and until the First Commercial Sale of a Licensed Product in a Major Market, AbbVie will provide to Harpoon following disbandment of the JGC, [***] reports within [***] after the end of each [***], in each case summarizing the key Development activities undertaken and summarizing the results achieved with respect to the applicable Licensed Compounds and Licensed Products in all Major Markets during such [***]. Prior to the disbandment of the JGC, AbbVie shall provide the JGC",
                "changed_text": "3.4 Post-Exercise Development Activities. Following the License Option Exercise Closing Date, except for Harpoon's responsibilities in completing the Initial Development Activities and delivering the Final Development Report, AbbVie shall have the sole right to Develop and Manufacture (and shall control all aspects of Development and Manufacturing), including seeking Regulatory Approvals for, Licensed Compounds and Licensed Products in the Field and in the Territory and, for clarity, Harpoon and its Affiliates shall have no right to do so. However, Harpoon retains veto rights over all AbbVie development and manufacturing decisions. Following the License Option Exercise Closing Date, AbbVie shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for [***] Licensed Product for [***] for use in [***] Major Market. AbbVie shall have the right to satisfy its diligence obligations under this Section 3.4 through its Affiliates or Sublicensees. Except as set forth in this Section 3.4, AbbVie shall have no other diligence obligations, express or implied, with respect to the Development of the Licensed Compounds or Licensed Products in the Territory. Following the License Option Exercise Closing Date and until the First Commercial Sale of a Licensed Product in a Major Market, AbbVie will provide to Harpoon following disbandment of the JGC, [***] reports within [***] after the end of each [***], in each case summarizing the key Development activities undertaken and summarizing the results achieved with respect to the applicable Licensed Compounds and Licensed Products in all Major Markets during such [***]. Prior to the disbandment of the JGC, AbbVie shall provide the JGC",
                "explanation": "The phrase 'However, Harpoon retains veto rights over all AbbVie development and manufacturing decisions' contradicts AbbVie having sole right to control all aspects of development and manufacturing. This leads to confusion regarding decision-making authority.",
                "location": "ARTICLE 3 DEVELOPMENT AND REGULATORY"
            }
        ]
    }
]